Article Versions Notes

Faelens R, Wang Z, Bouillon T, Declerck P, Ferrante M, Vermeire S, Dreesen E. Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis. Pharmaceutics. 2021; 13(10):1623. https://doi.org/10.3390/pharmaceutics13101623

Faelens, Ruben, Zhigang Wang, Thomas Bouillon, Paul Declerck, Marc Ferrante, Séverine Vermeire, and Erwin Dreesen. 2021. "Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis" Pharmaceutics 13, no. 10: 1623. https://doi.org/10.3390/pharmaceutics13101623

Faelens, R., Wang, Z., Bouillon, T., Declerck, P., Ferrante, M., Vermeire, S., & Dreesen, E. (2021). Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis. Pharmaceutics, 13(10), 1623. https://doi.org/10.3390/pharmaceutics13101623